Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis

British Journal of Dermatology

Volumn 152, Issue 5, 2005, Pages 1022-1025

  Grases, F ^a   Perello J ^a   Isern, B ^a   Prieto, R M ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

Calcinosis cutis; Crystallization inhibitor; Myo inositol hexaphosphate; Phytate

Indexed keywords

CALCIUM PHOSPHATE; CALCIUM SALT; PHYTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREAM; CRYSTALLIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SKIN CALCIFICATION; URINALYSIS;

ADMINISTRATION, CUTANEOUS; ANIMALS; CALCINOSIS; MALE; OINTMENTS; PHYTIC ACID; POTASSIUM PERMANGANATE; RATS; RATS, WISTAR; SKIN DISEASES;

EID: 18944362108     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06382.x     Document Type: Article

References (29)

1. Reed MA, de Luna AM, Holaysan JS, Gerardo LT. Calcinosis cutis in chronic renal failure diagnosed by fine needle aspiration. A case report. Acta Cytol 2002; 46:738-40.
2. Cambiaghi S, Imondi D, Gangi S, Vegni C. Fingertip calcinosis cutis. Cutis 2000; 66:465-7.
3. Jucgla A, Sais G, Curco N et al. Calcinosis cutis following liver transplantation: a complication of intravenous calcium administration. Br J Dermatol 1995; 132:275-8.
4. Chave TA, Varma S, Knight AG. Dystrophic calcinosis cutis in venous ulcers: a cause of treatment failure. Br J Dermatol 2001; 145:364.
5. Blane CE, White SJ, Braunstein EM et al. Patterns of calcification in childhood dermatomyositis. Am J Roentgenol 1984; 142:397-400.
6. Bruguier A, Texier P, Sluzewski W et al. [Calcinosis of childhood dermatomyositis. Apropos of 10 cases.]. Helv Paediatr Acta 1984; 39:47-54 (French).
7. Brenke A, Haupt R, Loreck D. Apatite and collagen as constituents of the calcium deposits in progressive scleroderma. Dermatol Monatssch 1986; 172:235-7.
8. Leroux JL, Pernot F, Fedou P et al. Ultrastructural and crystallographic study of calcifications from a patient with CREST syndrome. J Rheumatol 1983; 10:242-6.
9. Goldminz D, Barnhill R, McGuire J, Stenn KS. Calcinosis cutis following extravasation of calcium chloride. Arch Dermatol 1988; 124:922-5.
10. Schick MP, Schick RO, Richardson JA. Calcinosis cutis secondary to percutaneous penetration of calcium chloride in dogs. J Am Vet Med Assoc 1987; 191:207-11.
11. Kanda A, Uchimiya H, Ohtake N et al. Two cases of gigantic dystrophic calcinosis cutis caused by subcutaneous and/or intramuscular injections. J Dermatol 1999; 16:371-4.
12. Grases F, Simonet BM, Prieto RM, March JG. Phytate levels in diverse rat tissues: influence of dietary phytate. Br J Nutr 2001; 86:225-31.
13. 6 levels in tissues and biological fluids depending on dietary phytate. J Nutr Biochem 2001; 12:595-601.
14. Grases F, March JG, Prieto RM et al. Urinary phytate in calcium oxalate stone formers and healthy people. Scand J Urol Nephrol 2000; 34:162-4.
15. Grases F, Garcia-Ferragut L, Costa-Bauzá A, March JG. Study of the effects of different substances on the early stages of papillary stone formation. Nephron 1996; 73:561-8.
16. Grases F, Prieto RM, Simonet BM, March JG. Phytate prevents tissue calcifications in female rats. Biofactors 2000; 11:171-7.
17. Conte A, Pizá P, García-Raja A et al. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phyate). Arch Esp Urol 1999; 52:305-10.
18. Graf E, Eaton JW. Antioxidant functions of phytic acid. Free Radic Biol Med 1990; 8:61-9.
19. Hawkins PT, Poyner DR, Jackson TR et al. Inhibition of iron-catalysed hydroxyl radical formation by inositol polyphosphates: a possible physiological function for myo-inositol hexakisphosphate. Biochem J 1993; 294:929-34.
20. Graf E, Eaton JW. Dietary suppression of colonic cancer. Fiber or phytate? Cancer 1985; 56:717-8.
21. Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer agent. Life Sci 1997; 61:343-54.
22. Ishikawa T, Nakatsuru Y, Zarkovic M, Shamsuddin AM. Inhibition of skin cancer by IP6 in vivo: initiation-promotion model. Anticancer Res 1999; 19:3749-52.
23. Gupta KP, Singh J, Bharathi R. Suppression of DMBA-induced mouse skin tumor development by inositol hexaphosphate and its mode of action. Nutr Cancer 2003; 46:66-72.
24. Cooper CM, Sallis JD. Studies on the gastrointestinal absorption of phosphocitrate, a powerful controller of hydroxyapatite formation. Int J Pharm 1993; 98:165-72.
25. Demadis KD, Sallis JD, Raptis RG, Baran P. A crystallographically characterized nine-coordinate calcium-phosphocitrate complex as calcification inhibitor in vivo. J Am Chem Soc 2001; 123:10129-30.
26. Grases F, Perelló J, Isern B, Prieto RM. Determination of myo-inositol hexakisphosphate (phytate) in urine by inductively coupled plasma atomic emission spectrometry. Anal Chim Acta 2004; 510:41-3.
27. Valente M, Bortolotti U, Thiene G. Ultrastructural substrates of dystrophic calcification in porcine bioprostethic valve failure. Am J Pathol 1985; 119:12-21.
28. Grases F, Simonet BM, Vucenik I et al. Absorption and excretion of orally administered inositol hexaphosphate (IP (6) or phytate) in humans. Biofactors 2001; 15:53-61.
29. Grases F, Simonet BM, March JG, Prieto RM. Inositol hexakisphosphate in urine: the relationship between oral intake and urinary excretion. BJU Int 2000; 85:138-42.